VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
View in:
PubMed
subject areas
Adaptor Proteins, Signal Transducing
Administration, Oral
Adolescent
Adult
Aged
Cell Cycle Proteins
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Everolimus
Female
Humans
Killer Cells, Natural
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid, Acute
Leukemia, Prolymphocytic
Leukemia, T-Cell
Lymphoma, Mantle-Cell
Male
Maximum Tolerated Dose
Middle Aged
Myelodysplastic Syndromes
Phosphoproteins
Phosphorylation
Protein Kinases
Recurrence
Ribosomal Protein S6 Kinases, 70-kDa
Signal Transduction
Sirolimus
T-Lymphocytes
TOR Serine-Threonine Kinases
Treatment Outcome
Vasculitis, Leukocytoclastic, Cutaneous
authors with profiles
MICHAEL ANDREEFF
MARINA KONOPLEVA
FARHAD RAVANDI-KASHANI
ALESSANDRA FERRAJOLI
SRDAN VERSTOVSEK
WILLIAM G WIERDA
ZHIHONG ZENG